These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1554054)

  • 21. Tacrine and lecithin in Alzheimer's disease. Tacrine is safe and effective.
    Pendlebury WW; Solomon PR
    BMJ; 1994 Jun; 308(6942):1506; author reply 1507. PubMed ID: 8019290
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease.
    Jenike MA; Albert MS; Heller H; LoCastro S; Gunther J
    J Clin Psychiatry; 1986 May; 47(5):249-51. PubMed ID: 3700343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrine and lecithin in Alzheimer's disease. Patient heterogeneity explains varied response.
    Levy R
    BMJ; 1994 Jun; 308(6942):1506; author reply 1507. PubMed ID: 8019288
    [No Abstract]   [Full Text] [Related]  

  • 24. Tacrine and lecithin in Alzheimer's disease.
    BMJ; 1990 Apr; 300(6729):939-40. PubMed ID: 2337722
    [No Abstract]   [Full Text] [Related]  

  • 25. Dementia.
    Warner J; Butler R; Prabhakaran P
    Clin Evid; 2003 Jun; (9):1010-33. PubMed ID: 12967405
    [No Abstract]   [Full Text] [Related]  

  • 26. Tacrine and lecithin in Alzheimer's disease. Serum tacrine concentrations too low.
    Roberts C; Mäkelä P; Ford J; Truman C
    BMJ; 1994 Jun; 308(6942):1506; author reply 1507. PubMed ID: 8019289
    [No Abstract]   [Full Text] [Related]  

  • 27. Tacrine and lecithin in Alzheimer's disease. Negative conclusions not justified.
    Wilcock GK
    BMJ; 1994 Jun; 308(6942):1507. PubMed ID: 8019291
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease.
    Smith RC; Vroulis G; Johnson R; Morgan R
    Psychopharmacol Bull; 1984; 20(3):542-5. PubMed ID: 6433396
    [No Abstract]   [Full Text] [Related]  

  • 29. Lecithin and piracetam in Alzheimer's disease.
    Davidson M; Mohs RC; Hollander E; Zemishlany Z; Powchik P; Ryan T; Davis KL
    Biol Psychiatry; 1987 Jan; 22(1):112-4. PubMed ID: 3790634
    [No Abstract]   [Full Text] [Related]  

  • 30. Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
    Volger BW
    Clin Pharm; 1991 Jun; 10(6):447-56. PubMed ID: 2065522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report.
    Schneider LS; Lyness SA; Pawluczyk S; Gleason RP; Sloane RB
    Psychopharmacol Bull; 1991; 27(3):309-14. PubMed ID: 1775604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment.
    Kaye WH; Sitaram N; Weingartner H; Ebert MH; Smallberg S; Gillin JC
    Biol Psychiatry; 1982 Feb; 17(2):275-80. PubMed ID: 7074185
    [No Abstract]   [Full Text] [Related]  

  • 33. Tacrine in Alzheimer's disease.
    Lancet; 1991 Jun; 337(8755):1475-6. PubMed ID: 1675337
    [No Abstract]   [Full Text] [Related]  

  • 34. Tacrine for Alzheimer's disease.
    Med Lett Drugs Ther; 1993 Sep; 35(905):87-8. PubMed ID: 8361451
    [No Abstract]   [Full Text] [Related]  

  • 35. [Tacrine in the treatment of Alzheimer's disease].
    Weinstein HC; Teunisse S; van Gool WA; van Crevel H
    Ned Tijdschr Geneeskd; 1991 Aug; 135(35):1575-7. PubMed ID: 1922487
    [No Abstract]   [Full Text] [Related]  

  • 36. Alzheimer's: care does not end with drug therapy.
    Kelly BT
    Geriatrics; 1995 Jul; 50(7):7. PubMed ID: 7601362
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of Alzheimer disease with tacrine: a cost-analysis model.
    Wimo A; Karlsson G; Nordberg A; Winblad B
    Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):191-200. PubMed ID: 9437436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fee-for-service research on THA: an explanation.
    Summers WK
    N Engl J Med; 1987 Jun; 316(25):1605-6. PubMed ID: 3587296
    [No Abstract]   [Full Text] [Related]  

  • 39. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.
    Wilcock GK; Surmon DJ; Scott M; Boyle M; Mulligan K; Neubauer KA; O'Neill D; Royston VH
    Age Ageing; 1993 Sep; 22(5):316-24. PubMed ID: 8237620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tetrahydroaminoacridine (THA) in Alzheimer's disease.
    Byrne J; Arie T
    BMJ; 1989 Apr; 298(6677):845-6. PubMed ID: 2497817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.